The Centre for Targeted Therapy (CTT) was established by the Garvan Institute in 2015 as a centre of excellence to advance the development of new biological drugs. Biotechnology drugs, such as the anti-PD1 monoclonal antibody Pembrolizumab, are revolutionising the treatment of cancer and many inflammatory conditions.
The Centre operates state of the art equipment required for the measurement of macromolecular interactions and for the development and characterisation of candidate drugs, including surface plasmon resonance, biolayer interferometry and bioreactor systems.
Research at the CTT focuses on improving the transition of basic research into into drug candidates, products and treatments. The Centre is developing resources and events for the community to learn about biologics.
In the news
- NHMRC funding success for Garvan researchers - Nov 09, 2015
- No more money and time down the drain say antibody experts in Nature - Feb 05, 2015
- Start up company to commercialise antibody-stabilisation technology - Jan 15, 2015
- Making biologically active yet stable antibodies - Jun 28, 2012